



CASE D0323 NP

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV304408990US  
Express Mail Label Number

December 21, 2005  
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1649

RAMANATHAN ET AL.

Examiner: ULM, JOHN D.

APPLICATION NO: 10/800,249

FILED: MARCH 12, 2004

FOR: POLYNUCLEOTIDE ENCODING A NOVEL HUMAN G-PROTEIN  
COUPLED RECEPTOR VARIANT OF HM74, HGPRBMY74

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT


Sir:

Please charge Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

Respectfully submitted,

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
(609) 252-5289  
Date: December 21, 2005

  
Stephen C. D'Amico  
Agent for Applicants  
Reg. No. 46,652



CASE D0323 NP

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV304408990US  
Express Mail Label Number

December 21, 2005  
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1649

RAMANATHAN ET AL.

Examiner: ULM, JOHN D.

APPLICATION NO: 10/800,249

FILED: MARCH 12, 2004

FOR: POLYNUCLEOTIDE ENCODING A NOVEL HUMAN G-PROTEIN  
COUPLED RECEPTOR VARIANT OF HM74, HGPRBMY74

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c).  
A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the  
references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.


12/27/2005 HLE333 00000036 193880 10800249

01 FC:1806 180.00 DA

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,


Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
(609) 252-5289

  
\_\_\_\_\_  
Stephen C. D'Amico  
Agent for Applicants  
Reg. No. 46,652

Date: December 21, 2005

FORM PTO-1449  
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
D0323 NP  
APPLICATION NO.  
10/800,249  
APPLICANT  
RAMANATHAN ET AL.  
FILING DATE  
MARCH 12, 2004Group  
1649**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						

**FOREIGN PATENT DOCUMENTS**

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
AM						<input type="checkbox"/>	<input type="checkbox"/>
AN						<input type="checkbox"/>	<input type="checkbox"/>
AO						<input type="checkbox"/>	<input type="checkbox"/>

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

AR	Tanaru, et al., "Characterization of Determinants of Ligand Binding to the Nicotinic Acid Receptor GPR109A (HM74A/PUMA-G)", Molec. Pharm., Vol. 68(5), pp. 1271-1280 (2005)
AS	Tunaru, et al., "Site directed mutagenesis of the nicotinic acid receptor (HM74A) reveals a role of extracellular loop 1 and 2 in ligand binding and specificity", CS Univ Heidelberg, Inst Pharmacol, D-69120 Heidelberg, Germany SO Naunyn-Schmiedeberg's Archives of Pharmacology, (FEB 2005) Vol. 371, No. Suppl. 1, pp. R17. Meeting Info.: 46th Spring Meeting of the Deutsche-Gesellschaft-fur- Experimentelle-und-Klinische-Pharmakologie-und-Toxikologie. Mainz, GERMANY. March 15 -17, 2005. Deutsche Gesellsch Experimentelle Klinische Pharmakolog Toxikolog
AT	Benyo, et al. "The Thomson Corporation on STN TI Mechanism of nicotinic acid-induced flushing in mice", S. CS Univ Heidelberg, Inst Pharmacol, D-69120 Heidelberg, Germany SO Naunyn-Schmiedeberg's Archives of Pharmacology, (FEB 2005) Vol. 371, No. Suppl. 1, pp. R9. Meeting Info.: 46th Spring Meeting of the Deutsche-Gesellschaft-fur- Experimentelle-und-Klinische-Pharmakologie-und-Toxikologie. Mainz, GERMANY. March 15 -17, 2005. Deutsche Gesellsch Experimentelle Klinische Pharmakolog Toxikolog

**EXAMINER****DATE CONSIDERED**

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449  
(REV. 7-85)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.  
D0323 NP  
APPLICATION NO.  
10/800,249  
APPLICANT  
RAMANATHAN ET AL.  
FILING DATE  
MARCH 12, 2004

Group  
1649

# INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

2AA	Benyo, et al., "GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing", J. Clin. Investigation, Vol. 115 (12), pp. 3634-3640 (2005)
2AB	Pike, Nicholas B., "Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid", J. Clin. Investigation, Vol. 115 (12), pp. 3400-3403 (2005)
AC	
AD	
AE	
AF	
AG	
AH	
AI	
AJ	
AK	
AL	
AM	
AN	

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.